Literature DB >> 10068102

Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis.

W Bernal1, M Moloney, J Underhill, P T Donaldson.   

Abstract

BACKGROUND/AIMS: Primary sclerosing cholangitis is associated with the HLA haplotypes A1-B8-DRB3*0101-DRB1*0301-DQA1*0501-DQB1*0201 and DRB3*0101-DRB1*1301-DQA1*0103-DQB1* 0603. However, the interpretation of these genetic associations is controversial. One explanation may be that HLA-encoded susceptibility is due to other genes carried on these haplotypes such as the HLA class III tumor necrosis factor genes. The aim of the study was to investigate tumor necrosis factor genetics in a large series of well-defined patients.
METHODS: One hundred and ten HLA genotyped patients and 126 control subjects were studied by polymerase chain reaction genotyping for 3 different tumor necrosis factor gene polymorphisms: -308, -238 and an Ncol restriction fragment length polymorphism in the lymphotoxin alpha gene.
RESULTS: Overall, 58% of patients had the TNF2 allele, compared with 29% of controls, p(c) = 0.0001. No association was found with either of the other tumor necrosis factor polymorphisms examined. TNF2 was significantly increased in the presence of B8 and DRB3*0101 only, and was independent of DRB1*0301 (p(c)<0.04). The associations with B8 and TNF2 were stronger than the associations with any of the HLA class II alleles examined.
CONCLUSION: HLA-encoded genetic susceptibility to primary sclerosing cholangitis may be determined by polymorphism within the HLA class III region, in particular with the TNF2 allele.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10068102     DOI: 10.1016/s0168-8278(99)80068-3

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  12 in total

1.  Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLA-DRB1*13 but not with tumour necrosis factor alpha -308 promoter polymorphism.

Authors:  P L Bittencourt; S A Palacios; E L R Cançado; F J Carrilho; G Porta; J Kalil; A C Goldberg
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 2.  Immunopathogenesis of primary sclerosing cholangitis.

Authors:  Joy Worthington; Sue Cullen; Roger Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 3.  Etiopathogenesis of primary sclerosing cholangitis.

Authors:  Roger Chapman; Sue Cullen
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

4.  Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis.

Authors:  X Bo; U Broome; M Remberger; S Sumitran-Holgersson
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

5.  Cutting edge issues in primary sclerosing cholangitis.

Authors:  Christopher L Bowlus
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

6.  Quantitative assessment of the influence of tumor necrosis factor alpha polymorphism with gastritis and gastric cancer risk.

Authors:  Ming Li; Yinping Wang; Yahong Gu
Journal:  Tumour Biol       Date:  2013-09-27

7.  Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis.

Authors:  S A Mitchell; J Grove; A Spurkland; K M Boberg; K A Fleming; C P Day; E Schrumpf; R W Chapman
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

Review 8.  Genetics of primary sclerosing cholangitis and pathophysiological implications.

Authors:  Xiaojun Jiang; Tom H Karlsen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-03-15       Impact factor: 46.802

Review 9.  Primary sclerosing cholangitis: overview and update.

Authors:  Flavia Mendes; Keith D Lindor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-12       Impact factor: 46.802

Review 10.  Biliary atresia.

Authors:  Giorgina Mieli-Vergani; Diego Vergani
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.